Register

Downloads / CME Credit

Chair & Presenters

Harry P. Erba, MD, PhD
Chair and Presenter
Harry P. Erba, MD, PhD
University of Alabama at Birmingham
Birmingham, Alabama
Naval Daver, MD
Presenter
Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
Amir T. Fathi, MD
Presenter
Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Michael R. Savona, MD
Presenter
Michael R. Savona, MD
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee
Stephen A. Strickland, MD, MSCI
Presenter
Stephen A. Strickland, MD, MSCI
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Agenda

1:00 PM Welcome & Introduction: Progress in Validating Novel Therapy in AML


AML Master Classes: How Innovative Therapies Are Changing the Management of AML

1:10 PM Treatment Challenges in Secondary and Treatment-Related AML (Harry Erba, MD, PhD)


1:30 PM New Options in the Fight Against FLT3-Mutant AML: Established and Emerging Therapies (Stephen Strickland, MD, MSCI)


1:50 PM The Potential of Targeting IDH Mutations in AML (Michael Savona, MD)


2:10 PM Rethinking Antigen Targets and Antibody Therapy for Patients With AML (Amir Fathi, MD)


2:30 PM A Look at the Emergence of Immunotherapy in AML (Naval Daver, MD)


2:50 PM New Molecular Targets in AML—What Is the Current Status? (Harry Erba, MD, PhD)


3:10 PM Symposium Synthesis and Audience Q&A

CME Information

Activity Description & Educational Objectives

The management of acute myeloid leukemia (AML) is poised to make a leap into an era in which multiple novel options may be available to treat a range of complex AML presentations. Hematology-oncology professionals can soon expect more effective therapies in the wake of new science confirming the clinical potential of a range of novel agent classes (including targeted agents, newer antibodies, immune-based options, and newer cytotoxics) when used in conjunction with modern prognostic assessment techniques. In some cases, these new options for care are already available, with many more moving toward regulatory approval.

This PeerView Live CME-certified AML event—conducted in a “Master Class” case format—will feature multiple expert perspectives on modern AML treatment and illustrate how professionals can navigate an increasingly complex therapeutic landscape and effectively leverage the potency of newer agents across a variety of AML presentations—including patients with FLT3 or IDH mutant disease, the elderly, those with secondary AML, or those eligible for clinical trial–based treatment with antibodies or immunotherapy. Join the experts at this symposium and experience a deep dive into the science that is driving the rapidly emerging new era in AML patient care.

Upon completion of this activity, participants should be better able to:

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, medical oncologists and other clinicians involved in the management of patients with AML.

Requirements for Successful Completion

In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.

Media: Symposium
Release and Expiration Date: December 8, 2017
Time to Complete: 150 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Chair and Presenter

Harry P. Erba, MD, PhD
Albert F. LoBuglio Endowed Chair for Translational Cancer Research
Chair, SWOG Leukemia Committee
Professor, Internal Medicine
Director, Hematologic Malignancy Program
University of Alabama at Birmingham
Division of Hematology/Oncology
Birmingham, Alabama

Presenters

Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Michael R. Savona, MD
Director of Hematology Research
Associate Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Stephen A. Strickland, MD, MSCI
Hematology Clinical Service Line Chief
Clinical Director, Acute Leukemia
Division of Hematology/Oncology
Assistant Professor of Medicine
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent educational grants from AbbVie, Actinium Pharmaceuticals, Agios, Astellas Scientific and Medical Affairs, Inc., Celgene Corporation, and Jazz Pharmaceuticals, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

We invite you to attend our other symposia while at the conference. For our Friday dinner symposia, register here: peerviewpress.com/ALL17, or here: peerviewpress.com/HemA17.